Peluzio Maria do Carmo Gouveia, Dias Mariana de Moura E, Martinez J Alfredo, Milagro Fermín I
Department of Nutrition and Health, Universidade Federal de Viçosa, Viçosa, Brazil.
Department of Nutrition, Food Science and Physiology, Center for Nutrition Research, University of Navarra, Pamplona, Spain.
Front Nutr. 2021 Feb 22;8:638740. doi: 10.3389/fnut.2021.638740. eCollection 2021.
In the last decades changes in the pattern of health and disease in Latin America and in the world has been observed, with an increase in cases of chronic non-communicable diseases. Changes in intestinal microbiota composition can contribute to the development of these diseases and be useful in their management. In this context, the consumption of fermented foods with probiotic properties, such as kefir, stands out due to its gut microbiota-modulating capacity. There is an increasing interest in the commercial use of kefir since it can be marketed as a natural beverage containing health-promoting bacteria and has been gaining international popularity in Latin America. Also the consumption of these drinks in Latin America seems to be even more relevant, given the socioeconomic situation of this population, which highlights the need for disease prevention at the expense of its treatment. In this narrative review, we discuss how kefir may work against obesity, diabetes , liver disease, cardiovascular disorders, immunity, and neurological disorders. Peptides, bioactive compounds and strains occurring in kefir, can modulate gut microbiota composition, low-grade inflammation and intestinal permeability, which consequently may generate health benefits. Kefir can also impact on the regulation of organism homeostasis, with a direct effect on the gut-brain axis, being a possible strategy for the prevention of metabolic diseases. Further studies are needed to standardize these bioactive compounds and better elucidate the mechanisms linking kefir and intestinal microbiota modulation. However, due to the benefits reported, low cost and ease of preparation, kefir seems to be a promising approach to prevent and manage microbiota-related diseases in Latin America and the rest of the world.
在过去几十年中,拉丁美洲乃至全球的健康与疾病模式都发生了变化,慢性非传染性疾病的病例有所增加。肠道微生物群组成的变化可能会促使这些疾病的发展,并且对其治疗有益。在这种背景下,具有益生菌特性的发酵食品(如开菲尔)的消费因其对肠道微生物群的调节能力而备受关注。开菲尔的商业用途越来越受到关注,因为它可以作为一种含有促进健康细菌的天然饮料进行销售,并且在拉丁美洲越来越受到国际欢迎。考虑到该地区人群的社会经济状况,这些饮品在拉丁美洲的消费似乎更为重要,这凸显了以疾病预防而非治疗为重点的必要性。在这篇叙述性综述中,我们讨论了开菲尔如何对抗肥胖、糖尿病、肝脏疾病、心血管疾病、免疫和神经系统疾病。开菲尔中含有的肽、生物活性化合物和菌株可以调节肠道微生物群组成、减轻炎症和改善肠道通透性,从而可能带来健康益处。开菲尔还可以影响机体稳态的调节,直接作用于肠-脑轴,这可能是预防代谢性疾病的一种策略。需要进一步的研究来规范这些生物活性化合物,并更好地阐明开菲尔与肠道微生物群调节之间的联系机制。然而由于所报道的益处、低成本和易于制备,开菲尔似乎是拉丁美洲及世界其他地区预防和管理与微生物群相关疾病的一种有前景的方法。